Imigran (Sumatriptan)

Sumatriptan works by binding to serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings. This action causes vasoconstriction of dilated intracranial vessels and blocks the release of inflammatory neuropeptides, thereby interrupting the pain pathway that generates migraine symptoms.

The prescribed dose of Imigran is determined by the treating physician based on clinical guidelines, the severity of the migraine, and individual patient factors. Only a qualified healthcare professional should decide the appropriate amount and frequency of administration.

Safety of sumatriptan in pregnancy and lactation has not been definitively established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a healthcare provider.

To order Imigran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain handling if needed) and import documentation.

Imigran (sumatriptan injection) provides faster onset of relief compared with oral triptans because it is delivered subcutaneously. While oral formulations such as rizatriptan are convenient, the injectable route bypasses gastrointestinal absorption, making it useful for patients who need rapid symptom control or who have nausea that limits oral intake.

Imigran should be stored at 2‑8 °C in a refrigerator. Keep the product in its original packaging, protect it from light, and do not freeze or shake the prefilled syringes. If temporary storage at controlled room temperature is unavoidable, limit exposure to no more than 30 °C for a short period.

Imigran is supplied as a single‑use, prefilled syringe containing 6 mg of sumatriptan in 0.5 ml of solution. It is administered by subcutaneous injection, typically into the outer thigh or abdomen, following the technique recommended by the prescribing clinician.

Serious risks include chest discomfort or tightness that may signal cardiac ischemia, severe hypertension or rare cerebrovascular events such as stroke, coronary vasospasm, allergic reactions ranging from rash to anaphylaxis, and serotonin syndrome when combined with other serotonergic drugs. Patients should seek immediate medical attention if any of these symptoms occur.

Imigran is contraindicated in individuals with known coronary artery disease, uncontrolled hypertension, a history of cerebrovascular disease, hemiplegic or basilar migraine, and in patients who have experienced hypersensitivity to sumatriptan or any component of the formulation. It should also be avoided in patients taking monoamine oxidase inhibitors or other serotonergic agents without careful medical supervision.